This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ICON Forms Strategic Alliance With Boston Clinical Research Institute

ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a strategic alliance with Boston Clinical Research Institute (BCRI), an Academic Research Organisation based in Boston, Massachusetts. The alliance will combine BCRI’s respected leadership in clinical strategy, study planning and academic relationships with ICON’s experience in the execution of global clinical trials.

BCRI provides scientific consultancy in study design using expert practising clinicians and key opinion leaders from premier medical institutions, and also maintains a network of global investigators in all of the medical specialties and subspecialties. BCRI also provides academic leadership for Steering Committees, Advisory Panel Participation, Endpoint Committees, Core Laboratory Services, and Data Safety and Monitoring Boards.

“We are extremely pleased to announce the partnership with ICON,” commented Dr. Michael Gibson, Founder and Senior Consultant at BCRI. “We believe that the future of clinical research is collaboration between the ARO and the CRO. ICON clearly recognises the incremental benefits of collaboration with the thought leaders in the medical community to optimise study planning, execution, and credibility.”

Commenting on the alliance, Peter Gray, CEO at ICON plc, said, “We are delighted that Dr. Gibson and BCRI have aligned with ICON. The relationship provides ICON and its clients access to a breadth of expertise in the key opinion leader community and to investigators worldwide, including national and international leaders. Anticipated benefits include enhanced planning, design, site selection and enrolment performance.”

Jonathan Goldman MD FACC, Executive Vice President of Strategic Development at ICON Clinical Research, commented, “The relationship between BCRI and ICON further enhances our scientific expertise and access to investigators. We look forward to building on these relationships to enhance our feasibility services and to optimise the investment of our clients as a result of accelerated enrolment.”

Notes to Editors

About Dr. C. Michael Gibson, M.S.,M.D., F.A.C.C.

Dr. C. Michael Gibson MS, MD, FACC, is an Associate Professor of Medicine at Harvard Medical School and is a consulting Professor at the Duke School of Medicine. Gibson has led his own ARO for twenty years and has functioned as the principal investigator of numerous Phase I-IV clinical trials of up to 15,000 patients and as a senior investigator in the TIMI Study Group

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs